
The Library
Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease : a systematic review and meta-analysis of randomized trials
Tools
Ng, Khai P., Arnold, Julia, Sharif, Adnan, Gill, Paramjit, Townend, Jonathan N. and Ferro, Charles J. (2015) Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease : a systematic review and meta-analysis of randomized trials. Journal of the Renin-Angiotensin-Aldosterone System, 16 (3). pp. 599-613. doi:10.1177/1470320315575849 ISSN 1470-3203.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1177/1470320315575849
Abstract
Introduction:
The safety and actions of mineralocorticoid receptor antagonists on surrogate markers of cardiovascular disease as well as major patient level cardiovascular end-points in patients with chronic kidney disease are unclear.
Methods:
MEDLINE, EMBASE, Trip Database, Cochrane Central Register of Controlled Trials, Cochrane Renal Group specialized register, Current Controlled Trials and clinicaltrials.gov were searched for relevant trials.
Results:
Twenty-nine trials (1581 patients) were included. Overall, mineralocorticoid receptor antagonists lowered both systolic and diastolic blood pressure (–5.24, 95% confidence interval (CI) –8.65, −1.82 mmHg; p=0.003 and −1.96, 95% CI −3.22, –0.69 mmHg; p=0.002 respectively). There were insufficient data to perform a meta-analysis of other cardiovascular effects. However, a systematic review of the studies included suggested a consistent improvement in surrogate markers of cardiovascular disease. Overall, the use of mineralocorticoid receptor antagonists was associated with an increased serum potassium (0.23, 95% CI 0.13, 0.33 mmol/l; p<0.0001) and higher risk ratio (1.76, 95% CI 1.20, 2.57; p=0.001) of hyperkalemia. Data on long-term cardiovascular outcomes and mortality were not available in any of the trials.
Conclusions:
The long-term effects of mineralocorticoid receptor antagonists on cardiovascular events, mortality and safety need to be established.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Social Science & Systems in Health (SSSH) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Journal of the Renin-Angiotensin-Aldosterone System | ||||
Publisher: | Sage Publications Ltd. | ||||
ISSN: | 1470-3203 | ||||
Official Date: | 17 March 2015 | ||||
Dates: |
|
||||
Volume: | 16 | ||||
Number: | 3 | ||||
Page Range: | pp. 599-613 | ||||
DOI: | 10.1177/1470320315575849 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Open Access (Creative Commons) |
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |